Ameer Khowaja is an Endocrinology/Metabolic physician. OpenAlex indexes 33 publications with 207 citations (h-index 6).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
701 Park Ave
Minneapolis, MN 554151623
Telephone
612-873-6963Registry record last updated 10 Jul 2014.
Industry payments
59 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Insulet CorporationProgram year202533 payments
- Novo Nordisk IncProgram year202527 payments
- Amgen Inc.Program year202520 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
66%GLP-1 receptor agonist25.2%Ozempic58%Mounjaro33%Rybelsus9%Part D≥69 patientsInsulin Analog15.6%Tresiba Flextouch U-10023%Humalog Kwikpen U-10013%Lantus Solostar11%Humalog11%Toujeo Solostar10%Novolog Flexpen8%Insulin Lispro Kwikpen U-1006%Toujeo Max Solostar4%Insulin Lispro4%Soliqua 100-334%Basaglar Kwikpen U-1003%Novolog3%Part D<11 patients+ 5 more classes in this area
Cardiovascular
16.3%Statin9.7%Atorvastatin Calcium84%Rosuvastatin Calcium16%Part D≥59 patientsACE inhibitor2.2%Lisinopril61%Ramipril39%Part D<11 patients+ 4 more classes in this area
Hormonal (systemic)
16.2%l-Thyroxine15.1%Levothyroxine Sodium90%Synthroid11%Part D≥89 patientsThyroid Hormone Synthesis Inhibitor1.1%Methimazole100%Part D≥11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Continuous Glucose Monitoring (CGM) use in patients with diabetes mellitus type 1 is associated with higher healthcare costs, increased hospitalizations, and social disparities in a real-world setting: Analysis of adoption pattern, impact on health services utilization and cost of care in a large integrated health system
Diabetes Epidemiology and Management
2025 - Experimental pharmacological approaches to reverse impaired awareness of hypoglycemia—a review
Frontiers in Pharmacology
2024
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
Yousef Saleh Khader
Jordan University of Science and Technology
Jens Juul Holst
University of Copenhagen
Victor Montori, MD
Mayo Clinic
Christos Mantzoros, MD
Harvard Medical School
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”